Exploring Identity Transformation in Patients Undergoing CAR-T Cell Therapy
Main Article Content
Abstract
Gene therapy represents a major advancement in molecular medicine, offerin transformative treatments for hematological malignancies. Within this field, CAR- therapy has emerged as a novel intervention that extends survival but raises profoun psychological and existential questions for patients. Despite clinical success, little i known about how patients themselves experience the therapy, particularly in terms o hope, fear, and identity reconstruction. This study addresses that gap by asking: How d patients undergoing CAR-T therapy interpret and make sense of their lived experiences? Using an interpretative phenomenological approach, the study explored the narratives o ten patients recently treated with CAR-T therapy to capture the meanings they attach t this process. Semi-structured, in-depth interviews were conducted, and data wer analyzed thematically to identify essential patterns of meaning. The findings reveale four central themes: living with uncertainty and hope, transformation of identity and th body, emotional burden and psychosocial struggles, and negotiating the future. Patient described the therapy not only as a biomedical intervention but also as a deepl existential journey that reshaped their understanding of self and life trajectory. Overall, the abstract has been condensed to enhance readability and emphasize stud scope and participant clarity. These results highlight the limitations of conventiona quantitative assessments in capturing the essence of patient experiences and underscor the value of phenomenology in advancing patient-centered care. By foregrounding th subjective voices of patients, this study contributes to a more holistic framework fo evaluating gene-based therapies and offers directions for integrating psychosocia support into clinical practice.
Article Details
Section
References
Ababneh, H. S., Yee, A. J., Raje, N. S., Martin, S., Frigault, M. J., Ng, A. K., & Patel, C. G. (2023). Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy. Radiotherapy and Oncology, 189. Scopus. https://doi.org/10.1016/j.radonc.2023.109933
Akbari, B., Soltantoyeh, T., Shahosseini, Z., Yarandi, F., Hadjat, J., & Mirzaei, H. R. (2023). The inhibitory receptors PD1, Tim3, and A2aR are highly expressed during mesoCAR T cell manufacturing in advanced human epithelial ovarian cancer. Cancer Cell International, 23(1). Scopus. https://doi.org/10.1186/s12935-023-02948-0
Ali Hosseini Rad, S. M. A. H., Halpin, J. C., Tawinwung, S., Suppipat, K., Hirankarn, N., & McLellan, A. D. (2022). MicroRNA-mediated metabolic reprogramming of chimeric antigen receptor T cells. Immunology and Cell Biology, 100(6), 424–439. Scopus. https://doi.org/10.1111/imcb.12551
Atar, O., Ram, R., Avivi, I., Amit, O., Vitkon, R., Luttwak, E., Bar-On, Y., & Gidron, Y. (2023). Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma. Journal of Clinical Medicine, 12(3). Scopus. https://doi.org/10.3390/jcm12030908
Baer, B. (2021). Car t-cell therapy updates in nursing management. Clinical Journal of Oncology Nursing, 25(3), 255–258. Scopus. https://doi.org/10.1188/21.CJON.255-258
Barata, A., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Nelson, A. M., Yang, D., Karpinski, K., Holmbeck, K., Farnam, E., & Frigault, M. (2024). Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 30(4), 452-452.e11. Scopus. https://doi.org/10.1016/j.jtct.2024.01.063
Benzaquén, A., Giménez, E., Iacoboni, G., Guerreiro, M., Hernani, R., Albert, E., Carpio, C., Balaguer-Roselló, A., Pérez, A., & S de la Asunción, C. (2024). Torque Teno Virus plasma DNA load: A novel prognostic biomarker in CAR-T therapy. Bone Marrow Transplantation, 59(1), 93–100. Scopus. https://doi.org/10.1038/s41409-023-02114-0
Berning, P., Fekom, M., Ngoya, M., Goldstone, A. H., Dreger, P., Montoto, S., Finel, H., Shumilov, E., Chevallier, P., & Blaise, D. (2024). Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years. Blood Cancer Journal, 14(1). Scopus. https://doi.org/10.1038/s41408-024-01085-9
Beuchat, I., Danish, H. H., Rubin, D. B., Jacobson, C., Robertson, M., Vaitkevicius, H., & Lee, J. W. (2022). EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations. Neuro-Oncology, 24(2), 313–325. Scopus. https://doi.org/10.1093/neuonc/noab174
Farooqui, N., Sy-Go, J. P. T., Miao, J., Mehta, R., Vaughan, L. E., Bennani, N. N., Wang, Y., Bansal, R., Hathcock, M. A., & Hayman, S. R. (2022). Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy. Mayo Clinic Proceedings, 97(7), 1294–1304. Scopus. https://doi.org/10.1016/j.mayocp.2022.05.018
Fowler, N. H., Dickinson, M., Ghosh, M., Chen, A. I., Andreadis, C., Tiwari, R., Masood, A., Ramos, R., Jousseaume, E., & Thièblemont, C. (2023). Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study. Transplantation and Cellular Therapy, 29(1), 60-60.e4. Scopus. https://doi.org/10.1016/j.jtct.2022.09.022
Galtier, J., Vercellino, L., Chartier, L., Olivier, P., Tabouret-Viaud, C., Mesguich, C., Blasi, R. D., Durand, A., Raffy, L., & Gros, F.-X. (2023). Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells. Haematologica, 108(1), 171–180. Scopus. https://doi.org/10.3324/haematol.2021.280550
Georgi, T. W., Kurch, L., Franke, G.-N., Jentzsch, M., Schwind, S., Perez-Fernandez, C., Petermann, N., Merz, M., Metzeler, K., & Borte, G. (2023). Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy. Journal of Cancer Research and Clinical Oncology, 149(9), 6131–6138. Scopus. https://doi.org/10.1007/s00432-023-04587-4
Gu, R., Liu, F., Zou, D., Xu, Y., Lu, Y., Liu, B., Liu, W., Chen, X., Liu, K., & Guo, Y. (2020). Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. Journal of Hematology and Oncology, 13(1). Scopus. https://doi.org/10.1186/s13045-020-00953-8
Gust, J., Annesley, C. E., Gardner, R. A., & Bozarth, X. (2021). EEG Correlates of Delirium in Children and Young Adults with CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. Journal of Clinical Neurophysiology, 38(2), 135–142. Scopus. https://doi.org/10.1097/WNP.0000000000000669
Hamadani, M., Gopal, A. K., Pasquini, M., Kim, S., Qiu, X., Ahmed, S., Lazaryan, A., Bhatt, V., Daly, A., & Lulla, P. (2022). Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: A noncomparative cohort analysis. Blood Advances, 6(2), 486–494. Scopus. https://doi.org/10.1182/bloodadvances.2021005788
Han, L., Zhou, J., Zhou, K., Zhu, X., Zhao, L., Fang, B., Yin, Q., Wei, X., Zhou, H., & Li, L. (2020). Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus. Journal for ImmunoTherapy of Cancer, 8(2). Scopus. https://doi.org/10.1136/jitc-2020-000927
Hernani, R., Aiko, M., Victorio, R., Benzaquén, A., Pérez, A., Piñana, J. L., Hernández-Boluda, J. C., Amat, P., Pastor-Galán, I., & Remigia, M. J. (2024). EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome. Clinical Neurophysiology, 163, 132–142. Scopus. https://doi.org/10.1016/j.clinph.2024.04.014
Lefebvre, B., Kang, Y., Smith, A. M., Frey, N. V., Carver, J. R., & Scherrer-Crosbie, M. (2020). Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC: CardioOncology, 2(2), 193–203. Scopus. https://doi.org/10.1016/j.jaccao.2020.04.012
Lefebvre, B., Kang, Y., Vakilpour, A., Onoue, T., Frey, N. V., Brahmbhatt, P., Huang, B., Oladuja, K., Koropeckyj-Cox, D., & Wiredu, C. (2023). Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study. JACC: CardioOncology, 5(6), 747–754. Scopus. https://doi.org/10.1016/j.jaccao.2023.07.009
Lindsay, J., Krantz, E. M., Morris, J., Sweet, A., Tverdek, F., Joshi, A., Yeh, R., Hill, J. A., Greenwood, M., & Chen, S. C.-A. (2022). Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. Transplantation and Cellular Therapy, 28(8), 511-511.e10. Scopus. https://doi.org/10.1016/j.jtct.2022.05.030
Marón, G. M., Hijano, D. R., Epperly, R., Su, Y., Tang, L., Hayden, R. T., Naik, S., Karol, S. E., Gottschalk, S., & Triplett, B. M. (2022). Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy. Frontiers in Oncology, 12. Scopus. https://doi.org/10.3389/fonc.2022.845540
Mukhlis, L. (2025a). A Phenomenological Study of Personal Spiritual Experiences in Navigating Religious Pluralism within Interfaith Communities. Irfana: Journal of Religious Studies, 1(6), 212–220.
Mukhlis, L. (2025b). Spiritual Grounds for Economic Growth: A Qualitative Exploration of Rural Indonesian Women’s Transformative Journeys Through Mosque-Led Empowerment Programs. Servina: Jurnal Pengabdian Kepada Masyarakat, 1(8), 289–298.
Mukhlis, L., & Abdullah, M. N. (2025). Hukum Keluarga Islam di Indonesia (1st ed.). Mukhlisina Revolution Center.
Mukhlis, L., Arifin, T., Ridwan, A. H., & Zulbaidah. (2024). Integrating Artificial Intelligenceand Maqāṣid al-Syarī‘ah: Revolutionizing Indonesia’s Sharia Online Trading System. Computer Fraud and Security, 2024(11), 301–309. https://doi.org/10.52710/cfs.238
Mukhlis, L., Arifin, T., Ridwan, A. H., & Zulbaidah. (2025). Reorientation of Sharia Stock Regulations: Integrating Taṣarrufāt al-Rasūl and Maqāṣid al-Sharī‘ah for Justice and Sustainability. Journal of Information Systems Engineering and Management, 10(10s), 58–66. https://doi.org/10.52783/jisem.v10i10s.1341
Mukhlis, L., Arifin, T., Ridwan, A. H., Zulbaidah, Rosadi, A., & Solehudin, E. (2025). Reformulation of Islamic Stock Law: The Application of Taṣarrufāt al-Rasūl and Maqāṣid al-Syarī‘ahto Develop a Dynamic and Sustainable Islamic Capital Market in Indonesia. Journal of Posthumanism, 5(3), 1–13. https://doi.org/10.63332/joph.v5i3.913
Mukhlis, L., Janwari, Y., & Syafe`i, R. (2023). INDONESIA STOCK EXCHANGE: THEORETICAL AND PHILOSOPHICAL ANALYSIS OF MUDHARABAH AND MUSYARAKAH CONTRACTS. Yurisprudentia: Jurnal Hukum Ekonomi, 9(2), 243–264. https://doi.org/10.24952/yurisprudentia.v9i2.8466
Mukhlis, L., Maryam, S., & Sormin, S. A. (2023). Model Pembelajaran Living History Berbasis PjBL Untuk Meningkatkan Keterampilan Histografi Mahasiswa. Jurnal Educatio FKIP UNMA, 9(4), 1800–1809. https://doi.org/10.31949/educatio.v9i4.5595
Mukhlis, L., & Saidah, Y. (2025). Dynamics of Nature-Based learning in Developing Children’s Motoricic Skills: Teacher and Parent Perspectives. HUMANISMA: Journal of Gender Studies, 9(1), 64–79. http://dx.doi.org/10.30983/humanisme.v4i2.9366
Mukhlis, L., Suradi, Janwari, Y., & Syafe`i, R. (2023). Sosialisasi Saham Syariah sebagai Instrumen Pengembangan Ekonomi Masyarakat di Badan Kontak Majelis Taklim (BKMT) Kabupaten Mandailing Natal. Jurnal Pengabdian Multidisiplin, 3(2), 2–9. https://doi.org/10.51214/japamul.v3i2.604
Paul, F., Vicente, C., Courbon, C., Moreau, A.-S., Picard, M., Pochon, C., Stérin, A., Tudesq, J.-J., Yakoub-Agha, M., & Bay, J.-O. (2021). Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bulletin Du Cancer, 108(12), S90–S97. Scopus. https://doi.org/10.1016/j.bulcan.2021.11.001
Qi, J., Lv, X., Chen, J., Wang, H., Chu, T., Tang, Y., Pan, T., Zhou, M., Cai, C., & Ren, Y. (2022). TNF-α increases the risk of bleeding in patients after CAR T-cell therapy: A bleeding model based on a real-world study of Chinese CAR T Working Party. Hematological Oncology, 40(1), 63–71. Scopus. https://doi.org/10.1002/hon.2931
Qualls, D., & Salles, G. (2021). Optimizing CAR T cell therapy in lymphoma. Hematological Oncology, 39(S1), 104–112. Scopus. https://doi.org/10.1002/hon.2844
Reinert, C. P., Perl, R. M., Faul, C., Lengerke, C., Nikolaou, K., Dittmann, H., Bethge, W. A., & Horger, M. (2022). Value of CT-Textural Features and Volume-Based PET Parameters in Comparison to Serologic Markers for Response Prediction in Patients with Diffuse Large B-Cell Lymphoma Undergoing CD19-CAR-T Cell Therapy. Journal of Clinical Medicine, 11(6). Scopus. https://doi.org/10.3390/jcm11061522
Shadman, M., Ahn, K. W., Kaur, M., Lekakis, L., Beitinjaneh, A., Iqbal, M., Ahmed, N., Hill, B., Hossain, N. M., & Riedell, P. (2024). Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer Journal, 14(1). Scopus. https://doi.org/10.1038/s41408-024-01084-w
Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C., Durani, U., Burtis, M., Warsame, R., Paludo, J., & Gertz, M. A. (2022). Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant: PROs with CAR-T therapy versus Stem Cell Transplant. Transplantation and Cellular Therapy, 28(8), 473–482. Scopus. https://doi.org/10.1016/j.jtct.2022.05.004
Stenson, C. L., Vidrine, J., Dewhurst, F., Osborne, W., Menne, T., & Stocker, R. (2023). A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams. Palliative Medicine, 37(2), 215–220. Scopus. https://doi.org/10.1177/02692163221138880
Teipel, R., Kroschinsky, F., Krämer, M., Kretschmann, T., Egger-Heidrich, K., Krüger, T., Ruhnke, L., Herold, S., Stasik, S., & Sockel, K. (2022). Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Advances, 6(6), 1941–1946. Scopus. https://doi.org/10.1182/bloodadvances.2021005747